PhD, Associate Chief Physician, Head of the Radionuclide Therapy Subspecialty Group.
Affiliated HospitalRenji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
→
Research Areas : Integrated clinical and research work in nuclear medicine and radionuclide diagnosis and therapy; research on the intracellular retention mechanism of PSMA ligands in prostate cancer and strategies for enhancing the efficacy of PSMA-RLT. Cutting-Edge Technologies: Long-term experience in integrated clinical, research, and teaching work in nuclear medicine and radionuclide diagnosis and therapy; presented a report at the 2nd CSCO Annual Meeting on "Exploring the Intracellular Retention Mechanism of PSMA Ligands and Research on Strategies for Enhancing the Efficacy of PSMA-RLT in Prostate Cancer"; possesses extensive experience in PET diagnosis and radionuclide therapy for prostate cancer and thyroid diseases.
Areas of Expertise: PSMA PET diagnosis and radionuclide therapy for prostate cancer; radium-223 treatment for bone metastases in prostate cancer; diagnosis and treatment of hyperthyroidism/hypothyroidism/thyroid cancer/thyroid nodules. Academic Highlights: Member of the Clinical Integration Committee of the Nuclear Medicine Physicians Branch of the Chinese Medical Doctor Association; Member of the Nuclear Medicine Expert Committee of the Chinese Society of Clinical Oncology (CSCO); Member of the Tumor Nuclear Medicine Committee of the Shanghai Anti-Cancer Association; Deputy Leader of the Radionuclide Therapy Group of the Nuclear Medicine Specialty Branch of the Shanghai Medical Association; Principal investigator of one National Natural Science Foundation of China (NSFC) general program and participant in three NSFC projects; published over ten SCI papers as first author in journals such as *Molecular Cancer*, *JNM*, and *Radiology*.